BridgeBio Pharma (BBIO) shares were falling past 5% in recent Thursday trading after KKR Genetic Disorder disclosed the sale of 6 million BridgeBio shares in a regulatory filing.
KKR Genetic Disorder said in the filing that before BridgeBio's initial public offering, it bought about 167.7 million preferred units of BridgeBio for roughly $170.6 million in a series of financing deals.
The preferred units held by KKR Genetic Disorder were converted into about 34.3 million shares of BridgeBio, KKR Genetic Disorder said.
Price: 33.12, Change: -1.86, Percent Change: -5.30
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。